« Back
Home /
BSJ-02-162

BSJ-02-162

Item no.	HY-144995-50mg
Manufacturer	MedChem Express
CASRN	2139329-47-6
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 ea 25 mg 50 mg 5 mg
Category	Reagents & Chemicals Biochemicals
Type	Chemicals
Specific against	other
Purity	98.07
Formula	C43H49N11O7
Citations	[1]Nathanael S. Gray, et al. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use. WO2020023480 A1.
Smiles	O=C(NCCCCN1CCN(C2=CC=C(NC3=NC=C(C(C)=C(C(C)=O)C(N4C5CCCC5)=O)C4=N3)N=C2)CC1)CNC6=CC=CC(C(N7C(CC8)C(NC8=O)=O)=O)=C6C7=O
ECLASS 10.1	32160000
ECLASS 11.0	32160000
UNSPSC	12000000
Alias	CDK4/6-IN-11
Shipping condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	CDK; PROTACs
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	831.92
Product Description	CDK4/6-IN-11 is a potent PROTAC CDK4/6 degrader[1]. CDK4/6-IN-11 consists of a thalidomide-based E3 ligase ligand (blue part) Thalidomide-NH-CH2-COOH (HY-131717), a target protein ligand (red part) Palbociclib (HY-50767), and a PROTAC linker (black part) Boc-NH-C4-Br (HY-W007803). E3 ligase ligand and linker can form Thalidomide-NH-amido-C4-Br (HY-170307).
Manufacturer - Research Area	Cancer
Solubility	DMSO : 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Cell Cycle/DNA Damage; PROTAC
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-144995-50mg-safety-datasheet.pdf